{
    "ticker": "LABD",
    "name": "ProShares UltraPro Short Biotechnology",
    "description": "ProShares UltraPro Short Biotechnology (LABD) is an exchange-traded fund (ETF) that seeks to provide investors with a way to profit from declines in the biotechnology sector. Launched in 2013, LABD aims to deliver three times the inverse of the daily performance of the S&P Biotechnology Select Industry Index. This leveraged inverse strategy is designed for traders and sophisticated investors who anticipate market downturns and want to hedge their portfolios against bearish trends in the biotechnology industry. LABD invests primarily in biotechnology stocks, focusing on companies involved in the development of drugs, therapies, and medical technologies. Its portfolio typically includes a range of biotechnology firms, from large established players to smaller, high-growth companies. The fund offers a unique opportunity for investors to gain exposure to the biotech sector's volatility, making it a popular choice among day traders and those looking to capitalize on short-term price movements. However, due to its leveraged nature, LABD carries a higher risk and is not suitable for all investors. The fund is managed by ProShares, a leading provider of ETFs known for its innovative investment products.",
    "industry": [
        "Exchange-Traded Funds",
        "Biotechnology"
    ],
    "headquarters": "Bethesda, Maryland, USA",
    "founded": "2013",
    "website": "https://www.proshares.com/our funds/labd",
    "ceo": "Michael L. Sapir",
    "social_media": {
        "twitter": "https://twitter.com/ProShares",
        "linkedin": "https://www.linkedin.com/company/proshares"
    },
    "investor_relations": "https://www.proshares.com/investors/investor-relations",
    "key_executives": [
        {
            "name": "Michael L. Sapir",
            "position": "CEO"
        },
        {
            "name": "J. Adam Patti",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Inverse ETFs",
            "products": [
                "ProShares UltraPro Short Biotechnology (LABD)"
            ]
        }
    ],
    "seo": {
        "meta_title": "ProShares UltraPro Short Biotechnology (LABD) | Inverse Biotech ETF",
        "meta_description": "Invest in ProShares UltraPro Short Biotechnology (LABD), an ETF designed to profit from declines in the biotech sector. Explore our leveraged investment strategy.",
        "keywords": [
            "LABD",
            "ProShares",
            "Inverse ETF",
            "Biotechnology",
            "Leveraged Trading",
            "Short Selling"
        ]
    },
    "faq": [
        {
            "question": "What is LABD?",
            "answer": "LABD is an exchange-traded fund that seeks to provide three times the inverse of the daily performance of the S&P Biotechnology Select Industry Index."
        },
        {
            "question": "Who manages LABD?",
            "answer": "LABD is managed by ProShares, a leading provider of exchange-traded funds."
        },
        {
            "question": "What is the investment strategy of LABD?",
            "answer": "LABD employs a leveraged inverse strategy to profit from declines in the biotechnology sector."
        },
        {
            "question": "Is LABD suitable for all investors?",
            "answer": "Due to its leveraged nature, LABD carries higher risks and may not be suitable for all investors."
        },
        {
            "question": "When was LABD founded?",
            "answer": "LABD was founded in 2013."
        }
    ],
    "competitors": [
        "SQQQ",
        "TZA",
        "SH",
        "PSQ"
    ],
    "related_stocks": [
        "SPY",
        "XBI",
        "IBB",
        "ARKG"
    ]
}